XML 75 R64.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies - Additional Information (Detail)
3 Months Ended 9 Months Ended 24 Months Ended
Aug. 07, 2012
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
ft²
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
ft²
Dec. 31, 2014
USD ($)
Sep. 30, 2015
USD ($)
ft²
Dec. 31, 2014
USD ($)
Commitments And Contingencies [Line Items]                
Operating lease office space, in square feet | ft²     143,000       143,000  
Lease expiry period             June 2019  
Percentage of sublicensing income             10.00%  
Total consideration under current statement of work           $ 15,200,000    
Partial payment consideration under current statement of work             $ 1,000,000  
CureTech Ltd [Member]                
Commitments And Contingencies [Line Items]                
Potential payment upon completion of Manufacturing Technology Transfer             $ 5,000,000  
CureTech Ltd [Member] | MDV 9300 [Member]                
Commitments And Contingencies [Line Items]                
Upfront and setup fees       $ 200,000   $ 3,000,000    
Manufacturing services and supply agreement period             3 years  
Potential payment upon completion of Manufacturing Technology Transfer             $ 5,000,000  
Funding for clinical trial materials             19,300,000  
Clinical trial materials amount paid             $ 6,000,000  
Funding period for clinical materials             3 years  
Sixth Amendment To Lease Agreement [Member]                
Commitments And Contingencies [Line Items]                
Operating lease office space, in square feet | ft²         16,000      
Tenant improvement allowance         $ 300,000      
Outstanding letters of credit collateralized by restricted cash         $ 1,600,000      
Minimum lease payments over the lease term     $ 6,100,000       $ 6,100,000  
Development milestone payments [Member]                
Commitments And Contingencies [Line Items]                
Aggregate milestone payments upon achievement of certain development and regulatory milestone events     $ 2,800,000       $ 2,800,000  
Percentage of sublicensing income             10.00%  
Royalty percentage on sales             4.00%  
Sales milestone payments [Member] | Astellas Pharma Inc. [Member]                
Commitments And Contingencies [Line Items]                
Percentage of sublicensing income 10.00%   10.00%          
Eligible to receive milestone payments $ 320,000,000              
Sales milestone payments under collaborative agreement     $ 70,000,000       $ 145,000,000 $ 75,000,000
Payment related to sales milestones             $ 7,500,000  
Sales milestone payments [Member] | Astellas Pharma Inc. [Member] | Scenario, Forecast [Member]                
Commitments And Contingencies [Line Items]                
Payment related to sales milestones   $ 7,000,000